Supriya Lifescience Ltd
Supriya Lifescience Ltd Share Price Today: Live Updates & Key Insights
Get insights on Supriya Lifescience Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Supriya Lifescience Ltd Share Price Chart
SUPRIYA at 10 Jul 2026 06:26 PM Pharmaceuticals
854.60 -20.30(-2.32%)
Lowest Today 850.40
Highest Today 882.20
Today's Open 881.00
Prev. Close 874.90
52 Week High 1085.00
52 Week Low 545.50
Supriya Lifescience Ltd Fundamentals
Traded Volume: 2,38,089
Market Cap(Cr): 6,878.06
Avg Traded Price 861.85
1 Year return 20.50%
Upper Circuit 882.2
Lower Circuit 850.4
P/E TTM 33.00
P/B Ratio 5.879
Traded Value(Cr) 2034.71
EPS TTM 25.983
Book value/Share 148.810
Dividend Yield 1Y 0.12%
Supriya Lifescience Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Supriya Lifescience Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Supriya Lifescience Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -14.11%
1M -11.25%
3M +35.96%
1Y +20.50%
YTD +18.09%
Supriya Lifescience Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Supriya Lifescience Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 3.42L
Day Before Yesterday 6.76L
1W Avg 9.23L
1M Avg 5.33L
3M Avg 5.79L
Supriya Lifescience Ltd Technical Details
Supriya Lifescience Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 843
Support 2 831
Support 3 811
Pivot Point : 862
Resistance 1 874
Resistance 2 894
Resistance 3 906
Supriya Lifescience Ltd Corporate Actions
Supriya Lifescience Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Supriya Lifescience Ltd’s capital allocation strategies.
All
Ex-Date 04-Sep-2025 Type D Description 1.00/share@50.00% Record Date 05-Sep-2025 Ratio 50.00
Ex-Date 20-Sep-2024 Type D Description 0.80/share@40.00% Record Date - Ratio 40.00
Ex-Date 15-Sep-2023 Type D Description 0.60/share@30.00% Record Date 15-Sep-2023 Ratio 30.00
Ex-Date 01-Sep-2022 Type D Description 0.60/share@30.00% Record Date 02-Sep-2022 Ratio 30.00
Dividends
Announcement Date 04-Sep-2025 Ex Dividend Date 04-Sep-2025 Dividend(%) 50
Announcement Date 20-Sep-2024 Ex Dividend Date 20-Sep-2024 Dividend(%) 40
Announcement Date 15-Sep-2023 Ex Dividend Date 15-Sep-2023 Dividend(%) 30
Announcement Date 01-Sep-2022 Ex Dividend Date 01-Sep-2022 Dividend(%) 30
Bonus
No Bonus has been declared by SUPRIYA
Splits
No Split has been declared by SUPRIYA
Others
Rights No Rights has been declared by SUPRIYA
Supriya Lifescience Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Supriya Lifescience Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Supriya Lifescience Ltd's relative performance and valuation against major competitors.
Stock Name Sanofi India Ltd ₹3401.90 (+1.37%) M. Cap (Cr) 78.35 1 Yr Return (%) -43.33% P/E (TTM) 25.29 PB Ratio 10.22
Stock Name Jeena Sikho Lifecare Ltd ₹593.00 (+0.24%) M. Cap (Cr) 73.71 1 Yr Return (%) +7.73% P/E (TTM) 33.23 PB Ratio 15.78
Stock Name FDC Ltd ₹432.30 (+0.05%) M. Cap (Cr) 70.38 1 Yr Return (%) -14.45% P/E (TTM) 25.01 PB Ratio 2.83
Stock Name Supriya Lifescience Ltd ₹854.60 (-2.32%) M. Cap (Cr) 68.78 1 Yr Return (%) +20.50% P/E (TTM) 32.89 PB Ratio 5.74
Stock Name Senores Pharmaceuticals Ltd ₹1417.80 (-0.13%) M. Cap (Cr) 65.29 1 Yr Return (%) +141.45% P/E (TTM) 56.59 PB Ratio 6.99
Stock Name Aarti Pharmalabs Ltd ₹709.45 (+0.92%) M. Cap (Cr) 64.32 1 Yr Return (%) -22.29% P/E (TTM) 34.49 PB Ratio 3.03
Stock Name Innova Captab Ltd ₹989.35 (-0.15%) M. Cap (Cr) 56.62 1 Yr Return (%) +13.74% P/E (TTM) 40.18 PB Ratio 5.19
Supriya Lifescience Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Supriya Lifescience Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 185.77 Mar 2025 164.68 Mar 2024 113.31 Mar 2023 66.19 Mar 2022 48.80
PARTICULARS Investing Activities Mar 2026 -176.17 Mar 2025 -152.24 Mar 2024 -173.58 Mar 2023 -133.14 Mar 2022 -59.82
PARTICULARS Financing Activities Mar 2026 -9.88 Mar 2025 -8.23 Mar 2024 -22.36 Mar 2023 -3.37 Mar 2022 149.65
PARTICULARS Net Cash Flow Mar 2026 -0.29 Mar 2025 4.20 Mar 2024 -82.63 Mar 2023 -70.33 Mar 2022 138.63
Supriya Lifescience Ltd Shareholding Pattern
This shows the ownership breakdown of Supriya Lifescience Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 68.3%
Public 20.83%
Other Institutions 4.37%
FII 5.16%
Mutual Funds 1.33%
About Supriya Lifescience Ltd
Supriya Lifescience Limited was initially constituted on October 29, 1985, as a Partnership Firm under the name `M/s Supriya Chemicals'. The Partnership Firm was last re-constituted pursuant to a Partnership Deed dated November 30, 2007. Upon the conversion of `M/s Supriya Chemicals' the Partnership Firm into a Public Limited Company, the Company got incorporated as `Supriya Lifescience Limited' vide certified on March 26, 2008 by the Registrar of Companies, Mumbai. The Company commenced operations in April, 2008. It is engaged in manufacturing and export of active pharmaceutical ingredients (APIs). The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. The company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company's products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.The company's business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. In December 2021, the Company came up with an Initial Public Offer aggregating to Rs 700 crore out of which Rs 500 crore was Offer for Sale (OFS) and Rs 200 was Fresh Issue. In 2022-23, the Company acquired a manufacturing facility with the objective of commissioning backward integration projects. The Company initiated the construction of a new warehouse and administration block, which comprises a new quality control and assurance lab. It acquired plot of land at Isambe near Patalganga for capacity expansion. In 2025, the Company commissioned state-of-the-art Module E production block at Lote Parshuram, increasing the installed capacityfrom 597 KLPD to 932 KLPD.
Chairman / Executive Director / Managing Director
Satish Waman Wagh
Registered office 207/208 Udyog Bhavan, Sonawala Road Goregaon (East), Mumbai, Maharashtra, 400063
FAX :91-22-40332727
Background
Incorporation Year 2008
Face Value ₹2.00
Market Lot 1
FAQs on Supriya Lifescience Ltd
How to buy Supriya Lifescience Ltd shares?
To buy Supriya Lifescience Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Supriya Lifescience Ltd?
The company has a market capitalization of ₹6,878.06.
What is the PE & PB ratio of Supriya Lifescience Ltd?
PE is 33 and PB is 5.879.
What is the Supriya Lifescience Ltd dividend for 2025–26?
For the 2025–26 financial year, Supriya Lifescience Ltd declared a final dividend of 0.12% per share.